Yes, diltiazem is a prescription medication, so you should carry the original prescription label and a copy of the prescribing doctor's note. In the UK, the MHRA permits travel with up to a three-month supply, provided the medication is for personal use. Keep the tablets in their original packaging to avoid customs issues.
Extended-release diltiazem tablets are typically round and may be pink, blue, or white depending on the manufacturer and strength. Imprint codes such as “DIL 30”, “DIL 60”, “DIL 90”, or “DIL 120” identify the dosage. Check the packaging or patient information leaflet for the exact appearance of the brand you receive.
Diltiazem is not a prohibited substance on the World Anti-Doping Agency (WADA) list. Athletes competing under WADA rules can use diltiazem with a Therapeutic Use Exemption (TUE) if required for a legitimate medical condition.
Diltiazem can be combined with other antihypertensives such as ACE inhibitors, ARBs, or thiazide diuretics, but the combined effect may cause excessive blood-pressure reduction. Dose adjustments and close monitoring of blood pressure are advisable when multiple agents are prescribed.
No. Extended-release diltiazem tablets are formulated to release the drug gradually over several hours. Splitting, crushing, or chewing them destroys this mechanism, leading to a rapid release that can cause hypotension and bradycardia.
If stored correctly at room temperature, away from moisture and heat, the tablet retains its potency until the expiry date printed on the label. Once the bottle is opened, it is still safe to use for the duration indicated on the packaging, typically 24 months from the date of manufacture.
Yes. Immediate-release formulations are taken multiple times per day (often three to four doses) and have a quicker onset but shorter duration. Extended-release tablets are taken once daily, providing steadier plasma concentrations and better convenience for chronic therapy.
If you miss a dose and the next scheduled dose is more than six hours away, take the missed tablet as soon as you remember. If it is close to the time of your next dose, skip the missed tablet and continue with your regular schedule. Never double-dose to make up for a missed tablet.
Diltiazem is generally safe in asthma because it does not have the bronchoconstrictive beta-blocker activity seen with some other cardiovascular drugs. However, high doses may cause mild bronchodilation suppression; clinicians should assess respiratory status before initiating therapy.
Yes, diltiazem is available as a generic medication in the UK. Generic versions are typically priced lower than branded preparations, offering a cost-effective option for patients and the NHS. Prices may vary between pharmacies, so checking the NHS prescription charge exemption criteria is advisable.
Diltiazem is a prescription-only medication classified as a non-dihydropyridine calcium-channel blocker. It is available in oral pill form in strengths of 30 mg, 60 mg, 90 mg, and 120 mg. In the United Kingdom, diltiazem is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and is indicated for several cardiovascular conditions, including hypertension, chronic stable angina, and certain cardiac arrhythmias.
Diltiazem blocks L-type calcium channels primarily in the cardiac muscle and the vascular smooth muscle. By reducing calcium influx:
The onset of action after an oral dose is typically within 1-2 hours, with peak plasma concentrations occurring around 3-4 hours. The effects can persist for 12-24 hours, especially with the extended-release formulation. Diltiazem is metabolised extensively in the liver via the CYP3A4 enzyme and eliminated in the bile; only a small proportion is excreted unchanged in the urine.
Diltiazem is approved for the treatment of primary (essential) hypertension. By lowering systemic vascular resistance, it helps achieve target blood-pressure goals when used alone or in combination with other antihypertensive agents.
The drug relieves anginal chest pain by decreasing myocardial oxygen demand (through reduced heart rate and contractility) and by improving coronary blood flow via modest vasodilation.
In patients with atrial fibrillation or flutter, diltiazem slows AV-node conduction, reducing ventricular rate and alleviating symptoms such as palpitations and dyspnoea.
For some patients with HOCM, diltiazem may improve exercise capacity by decreasing outflow-tract gradients, although this indication is not universally approved in the UK.
Raynaud’s Phenomenon - Small clinical studies have demonstrated that low-dose diltiazem can reduce the frequency and severity of vasospastic attacks in secondary Raynaud’s, particularly when caused by connective-tissue disease. This use is not licensed in the UK and should only be undertaken under specialist supervision.
Cluster Headache Prophylaxis - Case series suggest that diltiazem may diminish attack frequency in patients with cluster headaches refractory to standard therapies. Because robust randomized trials are lacking, this application remains experimental and requires careful risk-benefit assessment.
All off-label applications must be prescribed by a qualified clinician after individualised evaluation.
These reactions are usually mild and transient; they often improve with dose adjustment or taking the medication with food.
If any of these occur, immediate medical evaluation is required.
| Dose (mg) | Typical Starting Regimen | Typical Maintenance Range | |--|--|| | 30 | 30 mg once daily | 30-60 mg once daily | | 60 | 60 mg once daily | 60-120 mg once daily | | 90 | - (usually titrated) | 90-120 mg once daily | | 120 | - (usually after titration) | 120 mg once daily (maximum) |
The exact regimen is determined by the treating clinician based on the indication, blood-pressure response, heart-rate control, and tolerability.
If a dose is missed and the next scheduled dose is more than 6 hours away, take the missed dose. If the next dose is imminent, skip the missed dose and continue the regular schedule. Do not double the dose.
Signs of overdose include pronounced bradycardia, hypotension, AV-block, and cardiac failure. Immediate actions:
Abrupt cessation may lead to rebound tachycardia or hypertension. When clinically appropriate, taper the dose gradually over 1-2 weeks, especially in patients on long-term therapy for arrhythmia control.
Patients should be instructed to seek medical attention promptly if they experience chest pain, significant dizziness, fainting, or new arrhythmic symptoms.
This article provides educational information about diltiazem and is not a substitute for professional medical advice. Treatment decisions, including the use of diltiazem for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
